|
US5521222A
(en)
*
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5461081A
(en)
*
|
1989-09-28 |
1995-10-24 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
JP2965267B2
(ja)
*
|
1992-02-21 |
1999-10-18 |
アルコン ラボラトリーズ，インコーポレイテッド |
局所用抗緑内障組成物
|
|
US5932572A
(en)
*
|
1992-02-21 |
1999-08-03 |
Alcon Laboratories, Inc. |
Topical anti-glaucoma compositions
|
|
AU3722793A
(en)
*
|
1992-09-17 |
1994-04-12 |
Alcon Laboratories, Inc. |
Topical carbonic anhydrase inhibitor composition
|
|
SE9301877D0
(sv)
*
|
1993-06-02 |
1993-06-02 |
Kabi Pharmacia Ab |
In situ gel for therapeutic use
|
|
CA2166722A1
(en)
*
|
1994-05-06 |
1995-11-16 |
Manoj L. Maniar |
Use of vitamin e tocopheryl derivatives in ophthalmic compositions
|
|
US6172054B1
(en)
|
1995-06-15 |
2001-01-09 |
Alcon Laboratories, Inc. |
Combination therapy for lowering and controlling intraocular pressure
|
|
US5696166A
(en)
*
|
1995-10-31 |
1997-12-09 |
Yanni; John M. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
WO1997018812A1
(en)
*
|
1995-11-17 |
1997-05-29 |
Alcon Laboratories, Inc. |
Combination therapy for treating glaucoma
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
FR2754712B1
(fr)
|
1996-10-17 |
1999-09-03 |
Merck Sharp Dohme Chibret Lab |
Compositions ophtalmiques
|
|
CH690814A5
(it)
*
|
1996-11-04 |
2001-01-31 |
Applied Pharma Res |
Composizioni per uso topico contenenti polisaccaridi solfati.
|
|
ZA989513B
(en)
|
1997-10-21 |
1999-04-21 |
Alcon Lab Inc |
Compositions containing histamine H2 agonists and methods of use in treating dry eye
|
|
US6174524B1
(en)
|
1999-03-26 |
2001-01-16 |
Alcon Laboratories, Inc. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
WO2000038690A2
(en)
|
1998-12-24 |
2000-07-06 |
Alcon Laboratories, Inc. |
Prostaglandin e agonists for treatment of dry eye
|
|
AU2183900A
(en)
|
1998-12-24 |
2000-07-31 |
Alcon Laboratories, Inc. |
Ep4 receptor agonists for treatment of dry eye
|
|
DE60024588T2
(de)
*
|
1999-01-25 |
2006-08-17 |
National Jewish Medical And Research Center, Denver |
Substituierte porphyrine und deren therapeutische verwendungen
|
|
AU8008300A
(en)
|
1999-11-01 |
2001-05-14 |
Alcon Inc. |
Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
|
|
US6552084B2
(en)
|
1999-11-09 |
2003-04-22 |
Alcon Universal Ltd. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
US6458854B2
(en)
|
1999-11-09 |
2002-10-01 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
US6803385B2
(en)
|
1999-11-09 |
2004-10-12 |
Alcon, Inc. |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
|
|
US6353032B1
(en)
|
1999-11-09 |
2002-03-05 |
Alcon Universal Ltd. |
Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
|
|
WO2001034553A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
|
|
PL356093A1
(en)
|
1999-11-09 |
2004-06-14 |
Alcon Inc. |
Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
|
|
CN1387435A
(zh)
|
1999-11-09 |
2002-12-25 |
爱尔康公司 |
用于治疗干眼的脂毒素a4及其衍生物
|
|
JP2003513948A
(ja)
|
1999-11-09 |
2003-04-15 |
アルコン，インコーポレイテッド |
１５−ｈｅｔｅの３−ヘテロ原子で置換され、かつ２個の炭素のホモログおよび使用方法
|
|
TR200201252T2
(tr)
|
1999-11-09 |
2003-02-21 |
Alcon, Inc. |
15-Hidroksieikosatetraenoik asit ile ilişkili bileşikler ve bunların kullanım yöntemleri
|
|
WO2001034129A2
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
|
|
AU8031400A
(en)
|
1999-11-09 |
2001-06-06 |
Alcon Universal Limited |
15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
|
|
WO2001034554A1
(en)
|
1999-11-09 |
2001-05-17 |
Alcon Universal Ltd. |
Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
|
|
AU775290B2
(en)
|
1999-11-09 |
2004-07-29 |
Alcon Inc. |
Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye
|
|
ATE296792T1
(de)
|
1999-11-09 |
2005-06-15 |
Alcon Inc |
Benzenoidderivate von 15- hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
|
|
AU2603301A
(en)
|
1999-12-22 |
2001-07-03 |
Alcon Universal Limited |
6-keto prostaglandin F1alpha and analogs for treating dry eye
|
|
CN1218689C
(zh)
|
2000-07-28 |
2005-09-14 |
爱尔康公司 |
包含妥布霉素和黄原胶的药物组合物
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
WO2002040056A2
(en)
|
2000-11-06 |
2002-05-23 |
Alcon, Inc |
Carrageenan viscoelastics for ocular surgery
|
|
US20030060447A1
(en)
*
|
2002-04-24 |
2003-03-27 |
Mutlu Karakelle |
Non-aspirating transitional viscoelastics for use in surgery
|
|
US6696453B2
(en)
|
2001-05-21 |
2004-02-24 |
Alcon, Inc. |
Use of NF-κB inhibitors to treat dry eye disorders
|
|
WO2002094311A1
(en)
|
2001-05-21 |
2002-11-28 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
BR0209882A
(pt)
*
|
2001-05-21 |
2004-06-08 |
Alcon Inc |
Método para o tratamento de distúrbios de olho seco
|
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
|
US6645994B1
(en)
|
2001-06-01 |
2003-11-11 |
Alcon, Inc. |
Method of treating dry eye disorders
|
|
WO2002098431A1
(en)
*
|
2001-06-01 |
2002-12-12 |
National Jewish Medical And Research Center |
Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
|
|
US6750250B1
(en)
|
2001-07-12 |
2004-06-15 |
Alcon, Inc. |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders
|
|
US20040214754A1
(en)
*
|
2001-10-03 |
2004-10-28 |
Ellis Edward J. |
Ophthalmic preparation containing glycomacropeptide
|
|
US20040220089A1
(en)
*
|
2001-10-03 |
2004-11-04 |
Ellis Edward J. |
Ophthalmic preparation containing glycoprotein
|
|
CA2464736A1
(en)
*
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
|
US20060234944A1
(en)
*
|
2001-10-23 |
2006-10-19 |
Oklahoma Medical Reseach Foundation |
Beta-secretase inhibitors and methods of use
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
AU2003213210A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
|
WO2003072141A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Pharmacia Corporation |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
|
EP2130541A3
(en)
|
2002-07-29 |
2013-12-18 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
|
WO2005018646A1
(ja)
*
|
2003-08-21 |
2005-03-03 |
Sucampo Ag |
眼科用組成物
|
|
US8580851B2
(en)
|
2002-08-21 |
2013-11-12 |
Sucampo Ag |
Ophthalmic solution
|
|
US20060217325A1
(en)
*
|
2002-12-20 |
2006-09-28 |
Alcon, Inc. |
Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells
|
|
ES2365223T3
(es)
|
2003-08-07 |
2011-09-26 |
Rigel Pharmaceuticals, Inc. |
Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
|
|
JP2008513497A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス，インコーポレーテッド |
メマプシン２βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法
|
|
JP2008513495A
(ja)
*
|
2004-09-17 |
2008-05-01 |
コメンティス，インコーポレーテッド |
ベータ−セクレターゼ活性を阻害する二環式化合物およびその使用方法
|
|
WO2006068760A2
(en)
*
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
|
AU2006235344B2
(en)
*
|
2005-04-08 |
2012-07-26 |
Comentis, Inc. |
Compounds which inhibit beta-secretase activity and methods of use thereof
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
TW200808375A
(en)
|
2006-05-12 |
2008-02-16 |
Otsuka Pharma Co Ltd |
Hydrogel suspension and manufacturing process thereof
|
|
EP2038272B8
(en)
|
2006-06-30 |
2013-10-23 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl pdk1 inhibitors
|
|
EP2420505A1
(en)
|
2006-11-21 |
2012-02-22 |
Rigel Pharmaceuticals, Inc. |
Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
|
|
KR20080076667A
(ko)
*
|
2007-02-15 |
2008-08-20 |
주식회사 중외제약 |
요변성 약학 조성물
|
|
HUE043228T2
(hu)
|
2007-06-22 |
2019-08-28 |
Univ Texas |
Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
|
|
CN101821238A
(zh)
*
|
2007-07-26 |
2010-09-01 |
科门蒂斯公司 |
抑制β-分泌酶(BETA-SECRETASE)活性的间苯二酰胺衍生物
|
|
MX2010002938A
(es)
*
|
2007-09-24 |
2010-04-01 |
Comentis Inc |
Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
|
|
US20110015158A1
(en)
|
2007-12-11 |
2011-01-20 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
|
WO2009110009A2
(en)
*
|
2008-03-07 |
2009-09-11 |
Sun Pharma Advanced Research Company Ltd., |
Opthalmic composition
|
|
CN102105146A
(zh)
|
2008-05-23 |
2011-06-22 |
国立犹太保健医院 |
用于治疗与暴露于烷化物质有关的损伤的方法
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
US8618096B2
(en)
*
|
2008-07-21 |
2013-12-31 |
The Regents Of The University Of California |
Prodrug compositions and methods for using the same in treating cancer and malaria
|
|
CA2737388C
(en)
|
2008-09-15 |
2017-07-11 |
Peter Walter |
Methods and compositions for modulating ire1, src, and abl activity
|
|
ES2624622T3
(es)
|
2008-12-30 |
2017-07-17 |
Rigel Pharmaceuticals, Inc. |
Inhibidores de pirimidindiamina cinasa
|
|
PL2389372T3
(pl)
|
2009-01-23 |
2016-02-29 |
Rigel Pharmaceuticals Inc |
Kompozycje i sposoby hamowania szlaku JAK
|
|
CN104523661A
(zh)
|
2009-02-06 |
2015-04-22 |
南加利福尼亚大学 |
含有单萜的治疗组合物
|
|
AU2010220061A1
(en)
*
|
2009-02-20 |
2010-09-10 |
Micro Labs Limited |
Storage stable prostaglandin product
|
|
AU2010281404A1
(en)
|
2009-07-28 |
2012-02-09 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
ES2608670T3
(es)
|
2009-08-17 |
2017-04-12 |
Memorial Sloan-Kettering Cancer Center |
Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
|
|
AR078320A1
(es)
|
2009-09-04 |
2011-11-02 |
Biogen Idec Inc |
Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
|
|
EP2485589A4
(en)
|
2009-09-04 |
2013-02-06 |
Biogen Idec Inc |
HETEROARYARY INHIBITORS OF BTK
|
|
LT2485731T
(lt)
|
2009-10-06 |
2016-09-12 |
Millennium Pharmaceuticals, Inc. |
Heterocikliniai junginiai, tinkami naudoti kaip pdk1 inhibitoriai
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
EP2853262B1
(en)
|
2009-10-26 |
2016-11-30 |
Sephoris Pharmaceuticals, LLC |
Treatment of sunburn using analgesics and antihistamines
|
|
CN102711765A
(zh)
|
2009-11-16 |
2012-10-03 |
加利福尼亚大学董事会 |
激酶抑制剂
|
|
ES2546063T3
(es)
|
2009-12-10 |
2015-09-18 |
The Regents Of The University Of California |
Agentes de enlace a amiloides
|
|
US8507734B2
(en)
|
2010-03-03 |
2013-08-13 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising monoterpenes
|
|
CN102918034B
(zh)
|
2010-03-30 |
2015-06-03 |
维颂公司 |
多取代芳族化合物作为凝血酶的抑制剂
|
|
PL2563771T3
(pl)
|
2010-04-24 |
2016-06-30 |
Viamet Pharmaceuticals Nc Inc |
Związki inhibitora metaloenzymu
|
|
CN103201280B
(zh)
|
2010-07-28 |
2016-08-10 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
US20160038600A1
(en)
|
2012-08-03 |
2016-02-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising poh derivatives
|
|
EP3173080B1
(en)
|
2010-08-27 |
2019-12-11 |
Neonc Technologies Inc. |
Pharmaceutical compositions comprising derivatives of perillyl alcohol
|
|
EP2632903A4
(en)
|
2010-10-28 |
2014-11-26 |
Viamet Pharmaceuticals Inc |
METALLOENZYMHEMMERVERBINDUNGEN
|
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
|
EA024197B1
(ru)
|
2010-11-13 |
2016-08-31 |
Иннокрин Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
EA201390876A1
(ru)
|
2010-12-13 |
2013-12-30 |
Вайамет Фармасьютикалс, Инк. |
Соединения, ингибирующие металлоферменты
|
|
BR112013015107B1
(pt)
|
2010-12-17 |
2022-03-22 |
Neonc Technologies Inc. |
Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico
|
|
EP2675786B1
(en)
|
2011-02-14 |
2018-12-26 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
|
CA2828360A1
(en)
|
2011-02-25 |
2012-08-30 |
The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services |
Chrysophaentin analogs that inhibit ftsz protein
|
|
CN103608028A
(zh)
|
2011-04-28 |
2014-02-26 |
南加利福尼亚大学 |
人类髓源抑制性细胞癌症标记
|
|
CA2836410C
(en)
|
2011-05-17 |
2019-08-20 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
KR102052670B1
(ko)
|
2011-05-17 |
2019-12-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키나아제 저해제
|
|
WO2012158795A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
US8809378B2
(en)
|
2011-06-19 |
2014-08-19 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
CA2839691A1
(en)
|
2011-06-19 |
2012-12-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
US8883797B2
(en)
|
2011-06-23 |
2014-11-11 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitor compounds
|
|
AU2012279154A1
(en)
|
2011-07-01 |
2014-02-20 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
|
WO2013063492A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
|
EP2788343B1
(en)
|
2011-12-11 |
2018-02-28 |
Viamet Pharmaceuticals (NC), Inc. |
Metalloenzyme inhibitor compounds
|
|
IN2014DN06792A
(da)
|
2012-01-20 |
2015-05-22 |
Viamet Pharmaceuticals Inc |
|
|
NZ629898A
(en)
|
2012-03-23 |
2016-04-29 |
Oxigene Inc |
Compositions and methods for inhibition of cathepsins
|
|
US20150087628A1
(en)
|
2012-04-10 |
2015-03-26 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
WO2013185082A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
CA2913736A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
|
ES2711425T3
(es)
|
2012-08-27 |
2019-05-03 |
Allergan Inc |
Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
|
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
LT3181567T
(lt)
|
2012-09-10 |
2019-07-25 |
Principia Biopharma Inc. |
Pirazolpirimidino junginiai kaip kinazės slopikliai
|
|
CA2886240A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
WO2014066435A1
(en)
|
2012-10-22 |
2014-05-01 |
City Of Hope |
Etp derivatives
|
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
|
EP2953950B1
(en)
|
2013-02-11 |
2021-01-13 |
The Regents of The University of California |
Compositions and methods for treating neurodegenerative diseases
|
|
WO2014143591A1
(en)
|
2013-03-12 |
2014-09-18 |
Allergan, Inc. |
Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
|
|
US9321745B2
(en)
|
2013-03-12 |
2016-04-26 |
Allergan, Inc. |
Inhibition of neovascularization by inhibition of prostanoid IP receptors
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
JP6422936B2
(ja)
|
2013-03-14 |
2018-11-14 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
５−ブロモ−インジルビン
|
|
CA2903827C
(en)
|
2013-03-14 |
2021-08-10 |
Stefan Oscarson |
Thiosaccharide mucolytic agents
|
|
JP2016519662A
(ja)
|
2013-03-14 |
2016-07-07 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｋ２ｐチャネルの調節
|
|
JP2016513647A
(ja)
|
2013-03-15 |
2016-05-16 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
レプチン生産を増進するビマトプロスト
|
|
PL2970346T3
(pl)
|
2013-03-15 |
2019-02-28 |
The Regents Of The University Of California |
Acykliczne diestry fosfonianowe nukleozydów
|
|
EP2968347B1
(en)
|
2013-03-15 |
2023-08-02 |
The Regents of the University of California |
Modulators of the eif2alpha pathway
|
|
BR112015023214A8
(pt)
|
2013-03-15 |
2019-12-24 |
Verseon Corp |
composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
|
|
ES2702182T3
(es)
|
2013-03-15 |
2019-02-27 |
Verseon Corp |
Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
|
|
WO2014146111A2
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Analgesic compounds and methods of use
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
WO2014190207A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
|
US9795691B2
(en)
|
2013-06-24 |
2017-10-24 |
City Of Hope |
Chemically-linked nanoparticles
|
|
CA2917527C
(en)
|
2013-07-15 |
2022-06-14 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
|
PT3035926T
(pt)
|
2013-08-19 |
2020-09-01 |
Univ California |
Compostos e métodos para tratar um distúrbio epiléptico
|
|
WO2015026935A2
(en)
|
2013-08-20 |
2015-02-26 |
City Of Hope |
Hdac8 inhibitors for treating cancer
|
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
WO2015089327A1
(en)
|
2013-12-11 |
2015-06-18 |
Biogen Idec Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
|
RS57662B1
(sr)
|
2013-12-11 |
2018-11-30 |
Biogen Ma Inc |
Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
|
|
BR112016014758A8
(pt)
|
2013-12-23 |
2020-06-02 |
Memorial Sloan Kettering Cancer Center |
composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto
|
|
RS58731B1
(sr)
|
2014-01-22 |
2019-06-28 |
Visufarma B V |
Kompozicija koja sadrži jota-karagenan protiv virusnog konjuktivitisa
|
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
|
HRP20220759T1
(hr)
|
2014-02-11 |
2022-09-02 |
Mitokinin, Inc. |
Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
|
|
CA2937752C
(en)
|
2014-02-14 |
2023-02-07 |
The Regents Of The University Of California |
Cyclic peroxides as prodrugs for selective delivery of agents
|
|
AU2015259752B2
(en)
|
2014-02-20 |
2019-06-20 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
|
MX2016010754A
(es)
|
2014-02-21 |
2017-03-03 |
Principia Biopharma Inc |
Sales y forma solida de un inhibidor btk.
|
|
US20150259288A1
(en)
|
2014-03-14 |
2015-09-17 |
City Of Hope |
5-bromo-indirubins
|
|
WO2015148839A1
(en)
|
2014-03-26 |
2015-10-01 |
City Of Hope |
Treatment of brca1-defective cancer or resistant cancers
|
|
ES2908240T3
(es)
|
2014-04-07 |
2022-04-28 |
Univ California |
Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
|
|
TWI699204B
(zh)
|
2014-05-13 |
2020-07-21 |
美國紀念斯隆 凱特琳癌症中心 |
Ｈｓｐ７０調節子及其製造及使用方法
|
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
|
US10414814B2
(en)
|
2014-07-03 |
2019-09-17 |
City Of Hope |
Tumor-selective CTLA-4 antagonists
|
|
US11072681B2
(en)
|
2014-07-28 |
2021-07-27 |
The Regents Of The University Of California |
Compositions and methods of making polymerizing nucleic acids
|
|
US10980744B2
(en)
|
2014-08-08 |
2021-04-20 |
The Regents Of The University Of California |
High density peptide polymers
|
|
CA2960992A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
Mtorc1 inhibitors
|
|
KR102589658B1
(ko)
|
2014-09-15 |
2023-10-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
뉴클레오타이드 유사체
|
|
AU2015317522A1
(en)
|
2014-09-17 |
2017-03-23 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
ES2757798T3
(es)
|
2014-10-02 |
2020-04-30 |
Allergan Inc |
Profármacos de éster de gamma-lactamas y su uso
|
|
SG11201704808VA
(en)
|
2014-12-18 |
2017-07-28 |
Principia Biopharma Inc |
Treatment of pemphigus
|
|
US10689423B2
(en)
|
2015-01-13 |
2020-06-23 |
City Of Hope |
CTLA4-binding protein peptide-linker masks
|
|
EA201791610A1
(ru)
|
2015-01-16 |
2017-12-29 |
Сити Оф Хоуп |
Проникающие в клетку антитела
|
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
|
JP6674957B2
(ja)
|
2015-02-12 |
2020-04-01 |
ネオンク テクノロジーズ インク． |
ペリリルアルコール誘導体を含む医薬組成物
|
|
WO2016138138A1
(en)
|
2015-02-25 |
2016-09-01 |
The Regents Of The University Of California |
5ht agonists for treating disorders
|
|
HRP20221287T1
(hr)
|
2015-02-27 |
2023-02-03 |
Verseon International Corporation |
Supstituirani pirazolni spojevi kao inhibitori serin proteaze
|
|
CA2977401A1
(en)
|
2015-02-27 |
2016-09-01 |
The Regents Of The University Of California |
Small molecules that enable cartilage rejuvenation
|
|
US20180244631A1
(en)
|
2015-02-27 |
2018-08-30 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
|
US11897952B2
(en)
|
2015-03-30 |
2024-02-13 |
City Of Hope |
Mechanically interlocking complexes
|
|
TW201702232A
(zh)
|
2015-04-10 |
2017-01-16 |
亞瑞克西斯製藥公司 |
經取代之喹唑啉化合物及其使用方法
|
|
CA2982360A1
(en)
|
2015-04-15 |
2016-10-20 |
Liansheng Li |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
|
WO2016166604A1
(en)
|
2015-04-17 |
2016-10-20 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
WO2016172726A1
(en)
|
2015-04-24 |
2016-10-27 |
The Regents Of The University Of California |
Modulators of ror1-ror2 binding
|
|
CN107849102B
(zh)
|
2015-05-15 |
2022-05-13 |
希望之城 |
嵌合抗原受体组合物
|
|
US10787664B2
(en)
|
2015-05-26 |
2020-09-29 |
City Of Hope |
Compounds of chemically modified oligonucleotides and methods of use thereof
|
|
WO2016201169A1
(en)
|
2015-06-10 |
2016-12-15 |
City Of Hope |
Compositions of and methods of treatment with zwitterionic polysaccharide
|
|
MA42510A
(fr)
|
2015-06-10 |
2018-06-06 |
Biogen Ma Inc |
Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
|
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
|
US10758624B2
(en)
|
2015-07-02 |
2020-09-01 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
DK3331879T3
(da)
|
2015-08-04 |
2020-08-10 |
Rigel Pharmaceuticals Inc |
Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
|
|
EP3331543A4
(en)
|
2015-08-06 |
2019-03-20 |
City of Hope |
CONJUGATES OF CELL PENETRATION FORMED OF PROTEIN AND ANTIBODIES AND METHODS OF USE
|
|
US11136301B2
(en)
|
2015-08-31 |
2021-10-05 |
The Regents of the University of California, A California Corporation et al. |
Broad spectrum antiviral compounds and uses thereof
|
|
US11124483B2
(en)
|
2015-09-02 |
2021-09-21 |
The Regents Of The University Of California |
HER3 ligands and uses thereof
|
|
EP3350167A4
(en)
|
2015-09-04 |
2019-04-03 |
City of Hope |
Androgen receptor Antagonist
|
|
WO2017051251A1
(en)
|
2015-09-25 |
2017-03-30 |
Ludwig Institute For Cancer Research Ltd |
3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10801026B2
(en)
|
2015-10-15 |
2020-10-13 |
City Of Hope |
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
CN108697699A
(zh)
|
2015-10-23 |
2018-10-23 |
苏尼西斯制药有限公司 |
用于治疗癌症的杂环pdk1抑制剂
|
|
CA3002924A1
(en)
|
2015-10-23 |
2017-04-27 |
Erx Pharmaceuticals Inc. |
Analogs of celastrol
|
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
|
TW201726656A
(zh)
|
2015-11-16 |
2017-08-01 |
亞瑞克西斯製藥公司 |
包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
JP7080813B2
(ja)
|
2015-12-10 |
2022-06-06 |
シティ・オブ・ホープ |
細胞透過性のシアニド結合抗体
|
|
BR112018012949B1
(pt)
|
2015-12-24 |
2023-11-14 |
The Regents Of The University Of California |
Reguladores cftr e métodos de uso dos mesmos
|
|
EP4071140A1
(en)
|
2015-12-24 |
2022-10-12 |
The Regents of The University of California |
Cftr regulators and methods of use thereof
|
|
MX2018008105A
(es)
|
2015-12-30 |
2018-11-12 |
Vps 3 Inc |
Compuestos inhibidores de metaloenzima.
|
|
CN108697690B
(zh)
|
2016-01-05 |
2022-01-14 |
加利福尼亚大学董事会 |
苯并噻唑两亲物
|
|
US10519442B2
(en)
|
2016-02-11 |
2019-12-31 |
City Of Hope |
Twist signaling inhibitor compositions and methods of using the same
|
|
BR112018068798A2
(pt)
|
2016-03-17 |
2019-01-22 |
Univ California |
composições e métodos para tratamento de doenças parasíticas
|
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
|
US20170312273A1
(en)
|
2016-04-25 |
2017-11-02 |
Forma Therapeutics, Inc. |
Methods of using fasn inhibitors
|
|
US20210323913A1
(en)
|
2016-04-29 |
2021-10-21 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
|
TWI763668B
(zh)
|
2016-05-05 |
2022-05-11 |
美商嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
TW201808914A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
|
CA3023490C
(en)
|
2016-05-12 |
2021-06-08 |
Anacor Pharmaceuticals, Inc. |
Oxaborole esters and uses thereof
|
|
CA3063834A1
(en)
|
2016-05-26 |
2017-11-30 |
The Regents Of The University Of California |
Estrogen receptor modulator combinations
|
|
ES2940911T3
(es)
|
2016-06-27 |
2023-05-12 |
Rigel Pharmaceuticals Inc |
Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
|
|
IL293621B2
(en)
|
2016-06-29 |
2023-09-01 |
Principia Biopharma Inc |
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
|
|
US11045493B2
(en)
|
2016-07-11 |
2021-06-29 |
The Regents Of The University Of California |
Synthetic melanin nanoparticles and uses thereof
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CA3031443A1
(en)
|
2016-07-21 |
2018-01-25 |
Biogen Ma Inc. |
Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
|
|
PL3490565T3
(pl)
|
2016-07-29 |
2022-09-26 |
Rapt Therapeutics, Inc. |
Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
|
WO2018053037A1
(en)
|
2016-09-13 |
2018-03-22 |
The Jackson Laboratory |
Targeted enhanced dna demethylation
|
|
CN109952104B
(zh)
|
2016-09-15 |
2023-03-28 |
希望之城 |
二硫etp衍生物
|
|
US10849955B2
(en)
|
2016-09-28 |
2020-12-01 |
City Of Hope |
Methods of treating pancreatic cancer using GPCR antagonists
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
EP3532470B1
(en)
|
2016-10-26 |
2022-12-07 |
Rigel Pharmaceuticals, Inc. |
Oxazole derivatives for use as irak inhibitors and method for their preparation
|
|
WO2018081294A1
(en)
|
2016-10-26 |
2018-05-03 |
Rigel Pharmaceuticals, Inc. |
Pyrazole amide compounds as irak inhibitors
|
|
US10646540B2
(en)
|
2016-11-18 |
2020-05-12 |
City Of Hope |
Peptide inhibitors of twist
|
|
WO2018102412A1
(en)
|
2016-11-30 |
2018-06-07 |
Neonc Technologies, Inc. |
A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
|
|
RU2019121922A
(ru)
|
2016-12-15 |
2021-01-18 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Композиции и способы лечения рака
|
|
FI3562487T3
(fi)
|
2016-12-29 |
2023-12-14 |
Ji Xing Pharmaceuticals Hong Kong Ltd |
Metalloentsyymi-inhibiittoriyhdisteitä
|
|
WO2018125799A2
(en)
|
2016-12-29 |
2018-07-05 |
Viamet Pharmaceuticals (Bermuda), Ltd. |
Metalloenzyme inhibitor compounds
|
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
US11274093B2
(en)
|
2017-01-26 |
2022-03-15 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
BR112019024674A2
(pt)
|
2017-05-25 |
2020-06-16 |
Araxes Pharma Llc |
Inibidores covalentes da kras
|
|
EP3630747A1
(en)
|
2017-05-25 |
2020-04-08 |
Araxes Pharma LLC |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
EP3641545A4
(en)
|
2017-06-21 |
2021-02-24 |
Mitokinin, Inc. |
COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
|
|
US10590121B2
(en)
|
2017-06-29 |
2020-03-17 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and methods for making and using
|
|
WO2019006371A1
(en)
|
2017-06-30 |
2019-01-03 |
City Of Hope |
COMPOSITIONS AND METHODS FOR MODULATING MACROPHAGE ACTIVITY
|
|
US11389460B2
(en)
|
2017-09-15 |
2022-07-19 |
City Of Hope |
Methods and compositions for treating endometrial cancer
|
|
JP2020536072A
(ja)
|
2017-09-29 |
2020-12-10 |
ジェネンテック， インコーポレイテッド |
ペプチド抗生物質複合体およびその使用方法
|
|
US20200354452A1
(en)
|
2017-09-29 |
2020-11-12 |
City Of Hope |
Cars and bispecific antibodies for treatment of mantle cell lymphoma
|
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
|
EP3694860A1
(en)
|
2017-10-10 |
2020-08-19 |
Syros Pharmaceuticals, Inc. |
Pyrrolotriazine compounds and methods of inhibiting tam kinases
|
|
US11618780B2
(en)
|
2017-10-20 |
2023-04-04 |
City Of Hope |
Composition and method for activating latent human immunodeficiency virus (HIV)
|
|
KR20200092332A
(ko)
|
2017-11-02 |
2020-08-03 |
칼리코 라이프 사이언시스 엘엘씨 |
통합된 스트레스 경로의 조절제
|
|
UY37958A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
EP3704115A1
(en)
|
2017-11-02 |
2020-09-09 |
Calico Life Sciences LLC |
Modulators of the integrated stress pathway
|
|
UY37956A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
CN112204012B
(zh)
|
2017-11-02 |
2023-12-26 |
卡里科生命科学有限责任公司 |
整合应激通路的调节剂
|
|
JP7184889B2
(ja)
|
2017-11-02 |
2022-12-06 |
カリコ ライフ サイエンシーズ エルエルシー |
統合的ストレス経路の調節剤
|
|
CN112218851A
(zh)
|
2017-11-02 |
2021-01-12 |
卡里科生命科学有限责任公司 |
整合应激通路的调节剂
|
|
CN112218869A
(zh)
|
2017-11-02 |
2021-01-12 |
卡里科生命科学有限责任公司 |
整合应激通路的调节剂
|
|
UY37957A
(es)
|
2017-11-02 |
2019-05-31 |
Abbvie Inc |
Moduladores de la vía de estrés integrada
|
|
AU2018360766A1
(en)
|
2017-11-06 |
2020-05-21 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
|
US20210292410A1
(en)
|
2017-12-07 |
2021-09-23 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
|
EP3720438B1
(en)
|
2017-12-07 |
2023-08-30 |
Amplyx Pharmaceuticals, Inc. |
Heterocycle substituted pyridine derivative antifungal agents
|
|
US11939575B2
(en)
|
2017-12-19 |
2024-03-26 |
City Of Hope |
Modified tracrRNAs gRNAs, and uses thereof
|
|
WO2019143730A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
WO2019143719A1
(en)
|
2018-01-16 |
2019-07-25 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
BR112020015056A2
(pt)
|
2018-01-26 |
2020-12-08 |
Rapt Therapeutics, Inc. |
Moduladores de receptor de quimiocina e usos dos mesmos
|
|
WO2019157195A1
(en)
|
2018-02-08 |
2019-08-15 |
Neonc Technologies, Inc |
Methods of permeabilizing the blood brain barrier
|
|
JP2021517893A
(ja)
|
2018-03-13 |
2021-07-29 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
|
|
CA3098562A1
(en)
|
2018-04-27 |
2019-10-31 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
AU2019262979B2
(en)
|
2018-05-01 |
2023-07-06 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mTOR inhibitors
|
|
TW202014208A
(zh)
|
2018-05-01 |
2020-04-16 |
美商銳新醫藥公司 |
作為ｍＴＯＲ抑制劑之Ｃ４０-、Ｃ２８-及Ｃ-３２連接之雷帕黴素類似物
|
|
ES2947446T3
(es)
|
2018-05-03 |
2023-08-09 |
Rigel Pharmaceuticals Inc |
Compuestos inhibidores de RIP1 y métodos para fabricar y usar los mismos
|
|
HUE063896T2
(hu)
|
2018-05-03 |
2024-02-28 |
Rigel Pharmaceuticals Inc |
RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása
|
|
EP3787618A4
(en)
|
2018-05-04 |
2022-05-04 |
Cirius Therapeutics, Inc. |
THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
|
|
US11046699B2
(en)
|
2018-06-05 |
2021-06-29 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
|
BR112020026086A2
(pt)
|
2018-06-21 |
2021-03-23 |
Calico Life Sciences Llc |
inibidores da proteína tirosina fosfatase e métodos de uso destes
|
|
EP3810115A4
(en)
|
2018-06-25 |
2022-03-02 |
Amplyx Pharmaceuticals, Inc. |
PYRID DERIVATIVES SUBSTITUTED BY A HETEROCYCLIC RING AND AN AMINO GROUP
|
|
US20210221864A1
(en)
|
2018-08-24 |
2021-07-22 |
City Of Hope |
Masked cytokine conjugates
|
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
|
CA3115897A1
(en)
|
2018-11-01 |
2020-05-07 |
Lynk Pharmaceuticals Co. Ltd. |
Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
|
|
US20220000880A1
(en)
|
2018-11-01 |
2022-01-06 |
Rigel Pharmaceuticals, Inc. |
Method and composition embodiments for treating acute myeloid leukemia
|
|
MA55301A
(fr)
|
2019-03-14 |
2022-01-19 |
Abbvie Inc |
Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
|
|
BR112021021703A2
(pt)
|
2019-04-30 |
2022-04-19 |
Abbvie Inc |
Cicloalquilas substituídas como moduladores da via de estresse integrada
|
|
CN114126596A
(zh)
|
2019-05-15 |
2022-03-01 |
贝克森生物医药公司 |
用于皮下注射的***制剂
|
|
US20200377518A1
(en)
|
2019-05-29 |
2020-12-03 |
Rigel Pharmaceuticals, Inc. |
Method of preventing and treating thrombosis
|
|
WO2021026451A1
(en)
|
2019-08-08 |
2021-02-11 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating cytokine release syndrome
|
|
CA3147444A1
(en)
|
2019-08-14 |
2021-02-18 |
Rigel Pharmaceuticals, Inc. |
Method of blocking or ameliorating cytokine release syndrome
|
|
MX2022002292A
(es)
|
2019-08-30 |
2022-06-02 |
Rigel Pharmaceuticals Inc |
Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones.
|
|
EP4025568A1
(en)
|
2019-09-06 |
2022-07-13 |
Rigel Pharmaceuticals, Inc. |
Rip1 inhibitory compounds and methods for making and using the same
|
|
CR20220075A
(es)
|
2019-09-06 |
2022-07-14 |
Rigel Pharmaceuticals Inc |
Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
|
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
JP2022548696A
(ja)
|
2019-09-18 |
2022-11-21 |
武田薬品工業株式会社 |
血漿カリクレインインヒビター及びその使用
|
|
BR112022004475A2
(pt)
|
2019-09-18 |
2022-05-31 |
Novartis Ag |
Proteínas de fusão nkg2d e usos das mesmas
|
|
KR20220079919A
(ko)
|
2019-11-07 |
2022-06-14 |
리겔 파마슈티칼스, 인크. |
헤테로시클릭 rip1 억제 화합물
|
|
JP2023501584A
(ja)
|
2019-11-13 |
2023-01-18 |
ラプト・セラピューティクス・インコーポレイテッド |
Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
|
|
WO2021127499A1
(en)
|
2019-12-18 |
2021-06-24 |
Calico Life Sciences Llc |
Protein tyrosine phosphatase inhibitors and methods of use thereof
|
|
KR20230012501A
(ko)
|
2020-05-19 |
2023-01-26 |
사이빈 아이알엘 리미티드 |
중수소화된 트립타민 유도체 및 사용 방법
|
|
JP2023540017A
(ja)
|
2020-08-18 |
2023-09-21 |
サイビン アイアールエル リミテッド |
治療用フェネチルアミン組成物およびその使用方法
|
|
KR20230129384A
(ko)
|
2020-11-02 |
2023-09-08 |
트레테라 코퍼레이션 |
데옥시시티딘 키나제 억제제의 결정형 및 이의 용도
|
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル，インク． |
医薬化合物の錯化剤塩製剤
|
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
|
US20220288047A1
(en)
|
2021-03-03 |
2022-09-15 |
Rigel Pharmaceuticals, Inc. |
Method for treating a disease or condition using a pyrazole compound or formulation thereof
|
|
TW202300490A
(zh)
|
2021-03-11 |
2023-01-01 |
美商雷傑製藥公司 |
雜環rip1激酶抑制劑
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
WO2022197756A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Plasma kallikrein inhibitors
|
|
WO2022197755A1
(en)
|
2021-03-17 |
2022-09-22 |
Shire Human Genetic Therapies, Inc. |
Imidazopyridinyl inhibitors of plasma kallikrein
|
|
AU2022240596A1
(en)
|
2021-03-17 |
2023-10-19 |
Takeda Pharmaceutical Company Limited |
Heteroaryl inhibitors of plasma kallikrein
|
|
EP4308564A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
|
JP2024512497A
(ja)
|
2021-03-17 |
2024-03-19 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤
|
|
WO2023156450A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Therapeutic phenethylamine compositions and methods of use
|
|
WO2023156453A1
(en)
|
2022-02-15 |
2023-08-24 |
Cybin Irl Limited |
Phenethylamine derivatives, compositions, and methods of use
|
|
US20230303555A1
(en)
|
2022-03-23 |
2023-09-28 |
Rigel Pharmaceuticals, Inc. |
Pyrimid-2-yl-pyrazole compounds as irak inhibitors
|
|
WO2023192479A1
(en)
|
2022-03-31 |
2023-10-05 |
Rigel Pharmaceuticals, Inc. |
Tricyclic irak inhibitors
|
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
CN114504550B
(zh)
*
|
2022-04-18 |
2022-08-19 |
中山大学中山眼科中心 |
一种包含甲硝唑的眼用凝胶及其制备方法
|